278. 巨大リンパ管奇形(頚部顔面病変) [臨床試験数:14,薬物数:15(DrugBank:7),標的遺伝子数:5,標的パスウェイ数:55]
Searched query = "Huge lymphatic malformation with cervicofacial lesion", "Huge lymphatic malformation", "Lymphatic malformation"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04128722 | November 15, 2019 | 11 November 2019 | TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN | TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN | Lingual Microcystic Lymphatic Malformations | Drug: Sirolimus Oral Liquid Product 1mg/mL | University Hospital, Tours | Not recruiting | 5 Years | N/A | All | 12 | Phase 2 | France | |
2 | NCT03972592 | June 5, 2019 | 16 September 2019 | Topical Sirolimus in Cutaneous Lymphatic Malformations | 0.1% Topical Sirolimus in the Treatment of Cutaneous Microcystic Lymphatic Malformations in Children and Adults: Phase II, Split-body Randomized, Double-blind, Vehicle-controlled Clinical Trial | Vascular Malformations;Lymphatic Malformation | Drug: Topical 0.1% Sirolimus;Drug: Topical Vehicle | University Hospital, Tours | University Hospital, Angers | Recruiting | 6 Years | N/A | All | 55 | Phase 2 | France |
3 | EUCTR2018-001359-11-FR | 22/02/2019 | 30 April 2019 | 0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial | 0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial - TOPICAL | Cutaneous microcystic lymphatic malformations (CMLM) in children and adults MedDRA version: 20.0 Level: LLT Classification code 10003229 Term: Arteriovenous malformations System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: Sirolimus 0,1% crème Pharmaceutical Form: Cream INN or Proposed INN: SIROLIMUS CAS Number: 53123-88-9 Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Cream Route of administration of the placebo: Cutaneous use | CHRU TOURS | Authorised | Female: yes Male: yes | 55 | Phase 2 | France | |||
4 | NCT03243019 | June 25, 2018 | 28 October 2019 | Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations | Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis | Lymphatic Malformation;Pediatric | Drug: rapamycin;Device: MRI;Biological: Rapamycin dosage | University Hospital, Lille | Ministry of Health, France | Recruiting | 1 Year | 18 Years | All | 28 | Phase 2 | France |
5 | JPRN-jRCTs031180290 | 16/11/2017 | 7 October 2019 | A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies | A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies - Sirolimus for intractable vascular anomalies | Intractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lympha Vascular disorders | Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. | Michio Ozeki | Recruiting | Not applicable | Not applicable | Both | 50 | Phase 3 | none | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | JPRN-UMIN000030522 | 2017/11/14 | 2 April 2019 | A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies | Intractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformations | Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. | Gifu University | Recruiting | Not applicable | Not applicable | Male and Female | 50 | Not selected | Japan | ||
7 | JPRN-jRCTs031180265 | 10/08/2016 | 10 September 2019 | Study of bleomycin and OK-432 combined scletotherapy for LMs | Clinical study of bleomycin and OK-432 combined local injection sclerotherapy for intractable lymphatic malformations | Lymphangioma (lymphatic malformation, common or cystic lymphatic malformation), and other lymphatic lymphangioma, lymphatic malformation,;D18.1 | OK-432 and bleomycin slolution (0.05 kE / mL and 0.5 mg / mL, respectively) will be injected into the lesion with water-soluble contrast agent Maximum dose of bleomycin is 10 mg /dose and 5 mg/kgBW.Cumulative maximum dose in repeated treatment is 10 mg/kgBW | Akihiro Fujino | Not Recruiting | Not applicable | Not applicable | Both | 21 | N/A | none | |
8 | NCT02335242 | May 23, 2015 | 15 April 2019 | Sildenafil for the Treatment of Lymphatic Malformations | Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations | Lymphatic Malformations;Lymphatic Diseases | Drug: Sildenafil 20 mg tablets;Other: Placebo tablets (resembling Revatio) | Stanford University | Ann & Robert H Lurie Children's Hospital of Chicago | Recruiting | 6 Months | 10 Years | All | 40 | Phase 2 | United States |
9 | ChiCTR-OPC-16008702 | 2014-05-01 | 18 April 2017 | Efficacy and safety of oral sildenafil in the treatment of pediatric lymphatic malformations in China | Sildenafil in the treatment of pediatric lymphatic malformations | pediatric lymphatic malformations | Sildenafil-treated group:oral sildenafil; | Beijing Children's Hospital | Recruiting | Both | Sildenafil-treated group:40; | Pilot study | China | |||
10 | JPRN-UMIN000008498 | 2012/07/25 | 2 April 2019 | Propranolol for a treatment of lymphatic malformation | lymphatic malformation | propranolol therapy | University of Tokyo | Not Recruiting | Not applicable | 65years-old | Male and Female | 20 | Phase 2 | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT01212965 | September 2010 | 19 February 2015 | Selenium in the Treatment of Complicated Lymphatic Malformations | Pilot Clinical Trial to Estimate the Safety and Efficacy of Selenium in the Treatment of Complicated Lymphatic Malformations in Adolescents and Young Adults | Lymphatic Malformations | Drug: Selenium | Medical College of Wisconsin | Not recruiting | 14 Years | 30 Years | Both | 5 | Phase 1 | United States | |
12 | NCT00975819 | October 2009 | 19 February 2015 | Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies | A Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies | Kaposiform Hemangioendotheliomas;Tufted Angioma;Capillary Venous Lymphatic Malformation;Venous Lymphatic Malformation;Microcystic Lymphatic Malformation;Mucocutaneous Lymphangiomatosis and Thrombocytopenia;Capillary Lymphatic Arterial Venous Malformations;PTEN Overgrowth Syndrome With Vascular Anomaly;Lymphangiectasia Syndromes | Drug: sirolimus | Children's Hospital Medical Center, Cincinnati | Not recruiting | N/A | 31 Years | Both | 60 | Phase 2 | United States | |
13 | NCT00010452 | April 2000 | 7 April 2015 | Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations | Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial | Lymphatic Malformations | Drug: picibanil | University of Iowa | Not recruiting | 6 Months | 18 Years | Both | 150 | Phase 2/Phase 3 | United States | |
14 | NCT03427619 | January 1, 1998 | 18 December 2018 | OK432 (Picibanil) in the Treatment of Lymphatic Malformations | OK432 (Picibanil) in the Treatment of Lymphatic Malformations | Lymphatic Malformations | Drug: OK432 | Richard JH Smith | Not recruiting | 6 Months | 17 Years | All | 701 | Phase 4 | United States |